Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
RIVER PDAC
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- NCT06989437 ↗
- Recruiting
- Pfizer
- Focused
We haven't built an HCP commentary report on RIVER PDAC yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RIVER PDAC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- ponsegromab; placebo
- Arms
- Double-Blind ponsegromab Treatment lower dose · Experimental
- Double-Blind ponsegromab Treatment higher dose · Experimental
- Double-Blind Placebo Treatment · Placebo comparator
- Enrollment
- 982 (estimated)
- Primary outcomes
- Percent change from baseline in body weight for ponsegromab compared to placebo
- Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores
- Sponsor
- Pfizer
- Start
- Oct 3, 2025
- Primary completion
- Jan 23, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06989437 · updated Oct 14, 2026